INFORCE™ 3 Earns Administration and Duration Label Claims
Added convenience and lasting protection against bovine respiratory disease
PARSIPPANY, N.J., Jan. 19, 2017 — Protection against respiratory disease early in life with INFORCE™ 3 helps calves stay healthy, develop to their full genetic potential and reduce the risk of illness later in life. Protecting young calves with INFORCE 3 is now easier than ever. INFORCE 3, the top selling cattle vaccine on the market1, has earned a single nostril administration claim to make it more convenient to administer.
Studies demonstrated that when the full 2-mL dose was administered into a single nostril in neonatal calves, INFORCE 3 protected against respiratory disease caused by infectious bovine rhinotracheitis (IBR)virus, bovine respiratory syncytial virus (BRSV) and parainfluenza 3 (PI3) virus.
In additional studies, INFORCE 3 also demonstrated the ability to override maternal antibodies to moderate IBR respiratory disease for at least 15 weeks and provided IBR respiratory protection for more than six months in IBR-naïve neonatal calves.
“INFORCE 3 delivers levels of protection and duration of immunity unmatched by any other intranasal vaccine,” said Nathan Voris, DVM, MBA, senior marketing manager with Zoetis. “Providing effective, long-lasting protection for the young calf is a big deal because illness during the calf’s first 60 days of life can set them back for their entire lifetime. Veterinarians and cattle producers utilize INFORCE 3 more than any other vaccine because they have observed the safe and effective respiratory protection it provides.”
Research underscores the benefits of INFORCE 3
Challenge studies investigating the efficacy of INFORCE 3 have demonstrated unsurpassed levels of protection for young calves.2-6
- In a severe BRSV challenge study in which only 10% of nonvaccinated calves survived respiratory infection, 100% of the calves vaccinated with INFORCE 3 were protected from mortality.
- Calves vaccinated in the presence of maternal antibodies and challenged with virulent IBR virus 105 days later demonstrated shorter disease duration, less respiratory disease incidence, less nasal shedding of virus and higher antibody titers than controls.
- IBR negative calves challenged with virulent IBR virus 193 days post-vaccination showed 75.7% less respiratory disease incidence versus controls.
These studies verify that vaccination of neonatal calves with INFORCE 3 offers an effective strategy for preventing BRSV respiratory disease and stimulates long-lasting IBR respiratory protection, even in the presence of IBR maternal antibodies.
“The fact INFORCE 3 prevents BRSV respiratory disease and has now been shown to protect calves against IBR respiratory disease for at least six months should provide additional confidence for everyone working to build successful calf immunization programs,” said Dr. Voris.
INFORCE 3 from Zoetis is the first and only respiratory vaccine that prevents respiratory disease caused by BRSV while also aiding in the prevention of IBR and PI3. Developed specifically for needle-free intranasal administration, INFORCE 3 has shown excellent efficacy in helping to prevent respiratory disease and reduce viral shedding.2-7
The vaccine contains proprietary temperature-sensitive IBR and PI3 viral strains, as well as naturally temperature-sensitive BRSV. This unique formulation stimulates protective immunity in the nasal passages, where respiratory infections start, while also priming the immune system for a rapid memory response to subsequent vaccination or disease challenge. INFORCE 3 is safe for use in all types, ages and classes of calves, including neonatal calves and weaned and high-stress stocker calves.
To learn more about INFORCE 3 and how it supports rapid, complete immune response, talk to your Zoetis representative or veterinarian. For additional resources about pneumonia prevention, visit DairyWellness.com
Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.
1 Animalytix® data, Zoetis Inc., September 2016.
2 Mahan SM, Sobecki B, Johnson J, et al. Efficacy of intranasal vaccination with a multivalent vaccine containing temperature-sensitive modified-live bovine herpesvirus type 1 for protecting seronegative and seropositive calves against respiratory disease. J Am Vet Med Assoc. 2016;248(11):1280-1286.
3 Data on file, Study Report No. 3131R-60-08-548, Zoetis Inc.
4 Data on file, Study Report No. 3131R-60-08-557, Zoetis Inc.
5 Data on file, Study Report No. 3131R-60-09-669, Zoetis Inc.
6 Data on file, Study Report No. 3131R-60-09-720, Zoetis Inc.
7 Data on file, Study Report No. 3131R-60-08-568, Zoetis Inc.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States